<DOC>
	<DOCNO>NCT00831922</DOCNO>
	<brief_summary>The objective study evaluate activity 2 oral dos AB1010 subject suffer active RA show inadequate response one DMARD include MTX anti-TNF , 3 month ( 12 week ) treatment . The safety efficacy evaluate : Rate patient achieve ACR 20 , 50 , 70 90 DAS ( disease activity score ) 3 month treatment ACRn 3 month treatment Therapeutic maintenance AB1010 3 month Quality Life assess SF12 Health Assessment Questionnaire ( HAQ ) Clinical biological safety Pharmacokinetic profile AB1010</brief_summary>
	<brief_title>Efficacy Oral AB1010 Adult Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>1 . Meet American College Rheumatology ( ACR ) criteria RA 2 . Have active RA 3 . ACR functional class IIII 4 . Disease onset &gt; 16 year age 5 . Disease duration least 6 month 6 . Failure one DMARD include methotrexate antiTNF alpha 1 . Pregnant breastfeed woman 2 . Inadequate bone marrow function 3 . Current use DMARD within 4 week ( 5 halflives , whichever long ) screen except leflunomide require specific washout 4 . Any previous use recombinant IL1Ra 5 . Current use 1 non steroidal antiinflammatory drug ( NSAID ) change dose NSAID within 4 week baseline NSAID use great maximum recommend dose 6 . Within 4 week baseline , use 10 mg/day prednisone equivalent change dose prednisone equivalent , intraarticular corticosteroid injection bolus intramuscular intravenous treatment corticosteroid ( &gt; 20 mg prednisone equivalent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>DMARD failure</keyword>
	<keyword>ACR</keyword>
</DOC>